You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥捷安康-B(02617.HK):替恩戈替尼聯用康方生物開坦尼®(卡度尼利,PD-1/CTLA-4)╱依達方®(依沃西,PD-1/VEGF)的II期臨牀試驗完成首例患者給藥
格隆匯 09-04 22:40

格隆匯9月4日丨藥捷安康-B(02617.HK)公告,公司核心產品替恩戈替尼(Tinengotinib,TT-00420)分別聯用康方生物科技(開曼)有限公司("康方生物")開坦尼®(卡度尼利,PD-1/CTLA-4)╱依達方®(依沃西,PD-1/VEGF)的治療晚期肝細胞癌(hepatocellularcarcinoma,HCC)的開放性、多中心II期臨牀研究,於近日完成首例患者給藥。

本試驗爲在中國開展的一項評價開坦尼®(卡度尼利,PD-1/CTLA-4)╱依達方(依沃西,PD-1/VEGF)聯合替恩戈替尼片治療晚期肝細胞癌療效和安全性的開放性、多中心、II期臨牀研究,試驗的主要目標爲評估開坦尼®(卡度尼利,PD-1/CTLA4)╱依達方(依沃西,PD-1/VEGF)分別聯合替恩戈替尼片或替恩戈替尼單藥治療晚期肝細胞癌的安全性和有效性。該試驗的主要目標人羣爲既往未接受過針對肝細胞癌的全身抗腫瘤治療或既往標準治療失敗後的晚期肝細胞癌患者。

藥捷安康已與康方生物訂立合作協議,雙方共同針對肝細胞癌領域開展臨牀聯合用藥開發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account